Webinar | May 26, 2017

Are Local IRBs Really Necessary In Starting Clinical Trials?

Source: goBalto

Many researchers have complained that use of different local IRBs to review each research site for a multicenter trial is extremely inefficient and leads to additional cost burdens and trial delays. Despite this, many US research sites have been hesitant to use a single, central IRB. Is there a substantive difference, in terms of efficiency and effectiveness, between reviews conducted by decentralized (local) and centralized IRBs? What are the pros and cons of each? Are local IRBs really even necessary, or do they just create bottlenecks in modern clinical trials? The webinar will focus on these issues and look at study startup metrics associated with IRBs.